7.2 Clinical Guidelines and Standards of Care

Official TCO knowledge in Domain III Planning includes evidence-based clinical guidelines and standards of care. ANCC is not asking you to memorize every footnote of every society PDF. It is asking you to know which U.S. authority owns the condition, to use the most recent applicable document from that owner, and to build a plan a reasonably prudent family NP would write — not a plan copied from a wellness blog or a 2012 pocket card.

How an FNP chooses a guideline

Start with the question type, then open the condition owner:

The exam rule of thumb: most recent applicable specialty guideline from the condition owner. Screening is USPSTF even if a cardiology blog “screens” everyone with a coronary calcium score. Vaccines are ACIP even if a school form is outdated. Diabetes drug selection is ADA (and the relevant kidney or heart guideline when the comorbidity is the reason for the drug). ANCC items usually follow U.S. primary-care consensus, not a European-only oddity and not a manufacturer slide deck.

Standards of care are what a reasonably prudent FNP in similar circumstances would do. Guidelines inform that standard; they are not automatically statutes. When you deviate — a 78-year-old who declines colonoscopy after a real risk-benefit talk — document the shared decision and the reason. When two reputable U.S. bodies conflict, the plan is not “pick the one you memorized in 2018.” The plan is to name the conflict, use the stem’s stated authority if it names one, and otherwise document shared decision-making.

Hypertension: 2025 AHA/ACC, PREVENT, race-neutral first line

This is the high-yield Planning update.

• Confirm hypertension with out-of-office measurements before labeling, unless the reading is a hypertensive emergency or the patient already has convincing end-organ disease.
• Categories still use 130/80 as the treatment-relevant cut: elevated 120–129 / <80; stage 1 130–139 or 80–89; stage 2 ≥140 or ≥90.
• The goal for most adults is <130/80, if tolerated.
• Risk discussion uses the PREVENT calculator, not the retired Pooled Cohort Equations as the 2025 text’s preferred engine.
• Lifestyle (sodium, weight, activity, alcohol, potassium-rich diet or a potassium-containing salt substitute when potassium and kidney function allow) is on every plan.
• First-line drugs: a thiazide-type diuretic, an ACE inhibitor, an ARB, or a dihydropyridine CCB, unless a compelling indication (HFrEF, albuminuric CKD, angina) chooses the class for you. Do not combine an ACE inhibitor with an ARB.
• First-line selection is race-neutral. Do not automatically write “Black patient, therefore CCB or thiazide only” as if race were a pharmacokinetic lab value. Treat the blood pressure, the comorbidities, and the whole-drug plan.
• Stage 2 usually starts pharmacotherapy (often two agents from different first-line classes if the reading is well into stage 2). Stage 1 starts medication when clinical CVD, diabetes, CKD, or elevated PREVENT 10-year risk as the current AHA/ACC text defines it is present. Use the threshold printed in the guideline or the stem; do not invent a private number.

Asthma: GINA 2025/2026 — no SABA-only

For adolescents and adults, every patient with asthma needs ICS-containing therapy. Track 1, preferred: ICS-formoterol as the anti-inflammatory reliever (AIR) and, when symptoms are more frequent, as maintenance-and-reliever therapy (MART). SABA-only treatment is not recommended — it is the classic outdated plan and a common exam trap. Track 2 (daily ICS plus a SABA reliever, or ICS whenever SABA is used) exists when Track 1 is not available or not accepted. Children have age-banded GINA tracks; do not copy the adult MART inhaler onto a preschooler without the pediatric table.

NAEPP/EPR-3 is older U.S. language (SABA plus stepped ICS). If a stem says “current GINA” or simply describes an adult who wants “just my albuterol,” the correct plan is ICS-containing therapy, preferably ICS-formoterol AIR/MART.

Other condition-owner rules worth a Planning item

GOLD COPD. Group by symptoms and exacerbations (A / B / E in current GOLD). Group E (exacerbations) is dual long-acting bronchodilation, with ICS added when blood eosinophils and exacerbation history support it — not a steroid inhaler for every smoker with a cough. Write the action plan (Section 7.1).

ADA diabetes. Diagnostic cutoffs (A1c ≥6.5%, fasting glucose ≥126 mg/dL, random ≥200 mg/dL with symptoms, or 2-hour OGTT ≥200) are Diagnosis. Planning is the A1c target (often <7% for many nonpregnant adults, individualized higher in frailty or limited life expectancy), metformin when appropriate, and organ-protective agents (SGLT2 inhibitor, GLP-1 receptor agonist) when heart failure, CKD, or atherosclerotic disease drives the choice — comorbidity, not a slogan, picks the drug.

ACIP. Build the schedule from the current child or adult schedule (Section 6.4). Package inserts and school forms lose when they disagree with ACIP.

CDC MEC / ACOG. MEC category 1 = no restriction, 2 = advantages outweigh risks, 3 = risks outweigh advantages (use only if no better method), 4 = unacceptable risk. Combined hormonal contraception is category 4 in several migraine-with-aura and early-postpartum settings — look up the condition; do not guess a category from memory if the stem is exotic.

IDSA. Use it when the stem is infection management (duration, first-line oral agent, when to image). Then check the local antibiogram. A 3-day nitrofurantoin plan for simple cystitis in a nonpregnant woman is an IDSA-shaped plan; 14 days of fluoroquinolone for the same syndrome is not.

USPSTF. Eligibility, grade, and interval — already taught as Assessment and as prevention level. In Planning, USPSTF tells you what belongs on the wellness plan and how strongly to offer it (A/B offer or provide; C selective; D discourage; I explain uncertainty).

When guidelines conflict

The durable example is mammography. Current USPSTF language is biennial screening from ages 40–74 for average-risk women. ACS uses a different start-and-interval pattern (shared decision 40–44, annual 45–54, then biennial or annual, continuing while health and life expectancy support it). Neither document is a blog. The FNP plan: name both if the patient asks, use USPSTF as the default primary-care offer unless the stem names ACS, individualize for higher-than-average risk, and document shared decision-making when the patient chooses the other reasonable U.S. schedule. Cervical screening (USPSTF vs ACS vs ACOG on cotesting intervals) is the same skill.

Do not “split the difference” into a schedule no body published. Do not follow a celebrity podcast over USPSTF. Do not tell the patient that ANCC forbids preference-sensitive choices.

Vignette. A 52-year-old woman has confirmed office and home blood pressures of 148/92, BMI 31, and infrequent asthma symptoms treated for years with albuterol alone. She wants to know whether to start mammograms “every year like my sister’s surgeon said.” The plan is one visit and three owners: 2025 AHA/ACC — start a race-neutral first-line antihypertensive, goal <130/80, lifestyle, PREVENT discussion; GINA — stop SABA-only, start ICS-formoterol AIR/MART; USPSTF biennial mammography 40–74 as the default offer, with documented SDM if she prefers the ACS annual pattern. That is guideline-based Planning.

If a stem names an authority, follow that authority. If it does not, follow U.S. primary-care consensus from the condition owner, and write down why.